Insilico Medicine Files for IPO to Leverage AI in Drug Discovery
China-based Insilico Medicine, a biotech company leveraging generative artificial intelligence (AI), has filed for an...
Pfizer’s Zavicefta Approved by China’s NMPA for Severe Infections in All Ages
US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China’s...
Amgen’s Tepezza Approved in UK for Thyroid Eye Disease Treatment
US biotech Amgen (NASDAQ: AMGN) announced that the UK’s Medicines and Healthcare products Regulatory Agency...
Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing
China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer...
Novo Nordisk Reports 18% YOY Revenue Growth in Q1 2025
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) released its Q1 2025 earnings report this week....
Sino Biopharmaceutical and JD Healthcare Forge Comprehensive Strategic Partnership
China-based Sino Biopharmaceutical Ltd (HKG: 1177) and JD Healthcare, a unit of China’s e-commerce giant...
Adicon Holdings Acquires Suzhou Youqin Medical Laboratory and Yuande Weikang
China-based independent clinic laboratory (ICL) service provider Adicon Holdings Ltd (HKG: 9860) announced the acquisition...
Oricell Partners with Umoja Biopharma to Develop In Vivo CAR-T Cell Therapies
China-based Oricell Therapeutics Co., Ltd. announced a strategic partnership agreement with US-headquartered Umoja Biopharma Inc....
BeiGene’s Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...
European Commission Approves J&J’s Tremfya for Crohn’s Disease Treatment
Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved Tremfya...
Amgen Reports 9% Revenue Growth in Q1 2025, Driven by Double-Digit Product Sales
US biotech Amgen (NASDAQ: AMGN) revealed its 2025 Q1 financial results, recording USD 8.1 billion...
AstraZeneca and Daiichi Sankyo Announce Positive DESTINY-Breast11 Trial Results for Enhertu
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the positive preliminary results from...
Siemens Healthineers Reports Q2 2025 Revenue Up 6.8% to EUR 5.909 Billion
Germany-based Siemens Healthineers AG (ETR: SHL) released its financial report for the second quarter of...
Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase...
Biogen Reports 8% YOY Sales Growth in Q1 2025, Driven by Rare Disease Therapies
According to Biogen Inc.’s (NASDAQ: BIIB) Q1 2025 report released this week, the US firm...
Zhongsheng Pharma’s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose...
Alchemab Therapeutics Licenses ATLX-1282 to Eli Lilly for ALS Treatment
UK-based biotech Alchemab Therapeutics Ltd entered into a licensing agreement with US major Eli Lilly...
China’s NMPA Releases Draft Guidelines for Development Risk Management Plan
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released the...
AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma
UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European...
Huadong Medicine’s HDM2005 Receives NMPA Approval for DLBCL Clinical Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...